Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-08-11 5:01 pm Sale | 13D | 89bio Inc. ETNB | RA CAPITAL MANAGEMENT L.P. | 12,874,814 16.7% | -2,084 (-0.02%) | View |
| 2023-08-09 5:00 pm Sale | 13D | DICE Therapeutics Inc. DICE | RA CAPITAL MANAGEMENT L.P. | 0 0% | -7,877,862 (Position Closed) | View |
| 2023-08-01 4:30 pm Purchase | 13G | NewAmsterdam Pharma Co N.V. NAMS | RA CAPITAL MANAGEMENT L.P. | 9,333,333 11.3% | 5,000,000 (+115.38%) | View |
| 2023-07-25 4:31 pm Purchase | 13D | ACUMEN PHARMACEUTICALS INC ABOS | RA CAPITAL MANAGEMENT L.P. | 14,981,618 25.9% | 5,207,067 (+53.27%) | View |
| 2023-07-06 4:32 pm Purchase | 13G | TOURMALINE BIO INC TRML | RA CAPITAL MANAGEMENT L.P. | 2,333,175 5.5% | 2,333,175 (New Position) | View |
| 2023-07-06 4:30 pm Purchase | 13G | UNICYCIVE THERAPEUTICS INC UNCY | RA CAPITAL MANAGEMENT L.P. | 3,470,689 9.99% | 3,470,689 (New Position) | View |
| 2023-06-27 5:00 pm Purchase | 13D | Aerovate Therapeutics Inc. AVTE | RA CAPITAL MANAGEMENT L.P. | 8,293,148 30% | 29,166 (+0.35%) | View |
| 2023-06-21 5:00 pm Purchase | 13D | DICE Therapeutics Inc. DICE | RA CAPITAL MANAGEMENT L.P. | 7,877,862 16.5% | 217,247 (+2.84%) | View |
| 2023-06-12 5:00 pm Sale | 13D | Satsuma Pharmaceuticals Inc. STSA | RA CAPITAL MANAGEMENT L.P. | 0 0% | -5,944,252 (Position Closed) | View |
| 2023-06-05 4:31 pm Purchase | 13G | 4D Molecular Therapeutics Inc. FDMT | RA CAPITAL MANAGEMENT L.P. | 2,789,721 6.7% | 2,789,721 (New Position) | View |
| 2023-05-30 5:00 pm Purchase | 13D | Icosavax Inc. ICVX | RA CAPITAL MANAGEMENT L.P. | 5,985,843 12.5% | 206,496 (+3.57%) | View |
| 2023-05-15 5:02 pm Sale | 13G | Travere Therapeutics Inc. TVTX | RA CAPITAL MANAGEMENT L.P. | 0 0% | -3,984,681 (Position Closed) | View |
| 2023-05-15 5:01 pm Sale | 13G | DA32 Life Science Tech Acquisition Corp. DALS | RA CAPITAL MANAGEMENT L.P. | 0 0% | -1,500,000 (Position Closed) | View |
| 2023-05-15 5:01 pm Sale | 13G | ARYA Sciences Acquisition Corp V ARYE | RA CAPITAL MANAGEMENT L.P. | 0 0% | -1,000,000 (Position Closed) | View |
| 2023-04-18 4:30 pm Purchase | 13D | Satsuma Pharmaceuticals Inc. STSA | RA CAPITAL MANAGEMENT L.P. | 5,944,252 17.9% | 30,000 (+0.51%) | View |
| 2023-04-10 5:05 pm Purchase | 13G | NanoString Technologies Inc NSTG | RA CAPITAL MANAGEMENT L.P. | 2,577,373 5.5% | 2,433,473 (+1691.09%) | View |
| 2023-04-10 5:01 pm Purchase | 13D | ELIEM THERAPEUTICS INC ELYM | RA CAPITAL MANAGEMENT L.P. | 13,163,071 48.8% | 11,112 (+0.08%) | View |
| 2023-04-10 5:00 pm Purchase | 13G | ASCENDIS PHARMA A/S SPONSORED ASND | RA CAPITAL MANAGEMENT L.P. | 9,967,172 17.4% | 3,009,993 (+43.26%) | View |
| 2023-03-30 5:08 pm Purchase | 13G | GH RESH PLC SHS GHRS | RA CAPITAL MANAGEMENT L.P. | 5,561,118 10.7% | 662,745 (+13.53%) | View |
| 2023-03-30 5:07 pm Purchase | 13D | Acrivon Therapeutics Inc. ACRV | RA CAPITAL MANAGEMENT L.P. | 4,817,359 22% | 3,917 (+0.08%) | View |